In Brief: Chantal Pharmaceutical
This article was originally published in The Rose Sheet
Chantal Pharmaceutical: Nets $6.8 mil. in a July 24 private placement of 1 mil. shares of common stock and 500,000 Series C Voting Convertible Preferred Stock shares (after payment of a 7.5% placement fee), the company announces Aug. 8. Chantal said the funds "will be used for general corporate purposes." In addition, Los Angeles-based Chantal expects its recently acquired lab in Arizona to be operational this fall. According to the firm, the lab will "triple Chantal's production capacity." The firm markets Chantal ethocyn-based skin care products ("The Rose Sheet" Nov. 28, In Brief) and is researching and developing both topical and systemic pharmaceutical products "for the treatment of androgen-mediated disorders...[and] certain cancers"...
You may also be interested in...
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle
The National Advertising Division concludes that by claiming the Schick Intuition Plus razor "lathers, shaves and moisturizes in one easy step," Energizer Personal Care is implying a long-term post-shave benefit comparable to that awarded by leave-on moisturizer, which is not supported by the company's evidence